-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
APIs, usually referred to as chemical APIs, are active ingredients in chemical pharmaceutical preparations, and are various medicinal powders, crystals, extracts, etc.
prepared by chemical synthesis, plant extraction or biotechnology
.
In recent years, except for the decline in 2020 due to the impact of the epidemic, the global API market has been showing a steady growth trend
.
It has risen from US$130.
8 billion in 2015 to US$175 billion in 2019, with a compound annual growth rate of 7.
5%
.
The API industry will usher in new opportunities for development.
At present, with the increase of a large number of patent expired drugs, the variety and quantity of generic drugs increase, and the production of APIs continues to grow.
The industry expects that the API market will reach 290 billion US dollars by 2026.
The compound annual growth rate is more than 10%
.
Among them, China's API market is also expected to exceed 400 billion yuan in 2022, with a growth rate of 8.
1%
.
The analysis believes that the development prospects of China's API market are very promising.
There are two main reasons: first, China's APIs have always played an important role in the global market, and since 2020, the status has been further improved due to the impact of the epidemic
.
According to preliminary statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, in the first half of 2021, China's API exports totaled US$19.
5 billion, a year-on-year increase of 14%
.
Secondly, in recent years, policies such as consistency evaluation and review reform have continued to increase, and industry barriers have gradually increased; the improvement of industry norms driven by pharmaceutical reform has also been laying the foundation for China's API and other related products to compete in the international market in the post-epidemic era
.
Therefore, under the multiple benefits, the development of China's API industry has been steadily moving forward
.
In addition to the continuous growth of the market, according to Claricate data, China currently has 1,482 API production bases.
Most of these production bases do not supply the regulated market and are expected to transform into a mature or more mature regulated market in the next 5-10 years.
supply company
.
At the same time, in the context of the increasingly standardized supply of domestic API companies, the superimposed industry continues to accumulate advantages in terms of cost, research and development, and the global supply chain restructuring caused by the epidemic, the development of China's API industry will usher in more many opportunities
.
It is worth mentioning that, in the context of the current promising prospects in the API industry, domestic pharmaceutical companies have actually begun to take action in order to better undertake the benefits
.
For example, a series of new or expanded large-scale API projects by a large number of enterprises are being started one after another
.
At the same time, some pharmaceutical companies have also embarked on the road of transformation around green development and high value-added products
.
For example, Twinings Bio plans to continue to adhere to the concept of green development and strengthen the resource utilization of by-products in the production process
.
Promote the innovation and upgrading of production technology and promote the green and low-carbon transformation of the industry; the green pharmaceutical industry base project invested and constructed by Tianke Pharmaceutical has been commissioned at the end of October last year.
The project aims to achieve green, intelligent and lean production of APIs and globalization
.
However, some analysts believe that under the steady growth of the API market, the industry concentration will continue to increase, and some small and medium-sized enterprises that cannot meet the needs of the industry will be eliminated in the future
.
In this context, domestic API companies should accelerate innovation and promote the transformation and upgrading of the industry towards green, low-carbon and high-quality development
.
prepared by chemical synthesis, plant extraction or biotechnology
.
In recent years, except for the decline in 2020 due to the impact of the epidemic, the global API market has been showing a steady growth trend
.
It has risen from US$130.
8 billion in 2015 to US$175 billion in 2019, with a compound annual growth rate of 7.
5%
.
The API industry will usher in new opportunities for development.
At present, with the increase of a large number of patent expired drugs, the variety and quantity of generic drugs increase, and the production of APIs continues to grow.
The industry expects that the API market will reach 290 billion US dollars by 2026.
The compound annual growth rate is more than 10%
.
Among them, China's API market is also expected to exceed 400 billion yuan in 2022, with a growth rate of 8.
1%
.
The analysis believes that the development prospects of China's API market are very promising.
There are two main reasons: first, China's APIs have always played an important role in the global market, and since 2020, the status has been further improved due to the impact of the epidemic
.
According to preliminary statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, in the first half of 2021, China's API exports totaled US$19.
5 billion, a year-on-year increase of 14%
.
Secondly, in recent years, policies such as consistency evaluation and review reform have continued to increase, and industry barriers have gradually increased; the improvement of industry norms driven by pharmaceutical reform has also been laying the foundation for China's API and other related products to compete in the international market in the post-epidemic era
.
Therefore, under the multiple benefits, the development of China's API industry has been steadily moving forward
.
In addition to the continuous growth of the market, according to Claricate data, China currently has 1,482 API production bases.
Most of these production bases do not supply the regulated market and are expected to transform into a mature or more mature regulated market in the next 5-10 years.
supply company
.
At the same time, in the context of the increasingly standardized supply of domestic API companies, the superimposed industry continues to accumulate advantages in terms of cost, research and development, and the global supply chain restructuring caused by the epidemic, the development of China's API industry will usher in more many opportunities
.
It is worth mentioning that, in the context of the current promising prospects in the API industry, domestic pharmaceutical companies have actually begun to take action in order to better undertake the benefits
.
For example, a series of new or expanded large-scale API projects by a large number of enterprises are being started one after another
.
At the same time, some pharmaceutical companies have also embarked on the road of transformation around green development and high value-added products
.
For example, Twinings Bio plans to continue to adhere to the concept of green development and strengthen the resource utilization of by-products in the production process
.
Promote the innovation and upgrading of production technology and promote the green and low-carbon transformation of the industry; the green pharmaceutical industry base project invested and constructed by Tianke Pharmaceutical has been commissioned at the end of October last year.
The project aims to achieve green, intelligent and lean production of APIs and globalization
.
However, some analysts believe that under the steady growth of the API market, the industry concentration will continue to increase, and some small and medium-sized enterprises that cannot meet the needs of the industry will be eliminated in the future
.
In this context, domestic API companies should accelerate innovation and promote the transformation and upgrading of the industry towards green, low-carbon and high-quality development
.
